VIENNA—Despite the proliferation of genetic tests for breast cancer recurrence risk these cannot yet reliably be used to predict late recurrences. So said Daniel Hayes MD, Clinical Director of the Breast Oncology Program at the University of Michigan Cancer Center Ann Arbor. After his talk on the utility of genetic signatures to select adjuvant treatment he discussed his findings and conclusions with Oncology Time reporter Sarah Maxwell.
You may also like...
Metastatic renal cell carcinoma: biomarkers to guide future therapy 25 Feb, 2014 Reassurance on Ductal Carcinoma in Situ (DCIS) Treatment De-Escalation 17 Apr, 2018 ASCO Audio Journal of Oncology – June 1st, 2006 – In the company of Gordon McVie 30 May, 2006 Blood test for free tumour DNA could guide breast cancer therapy 3 Apr, 2013
- Previous story New Strategies for Preventing ER-Negative Breast Cancer
- Next story Endocrine Therapy in Premenopausal Breast Cancer: Most Effective Not Always Best
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014